Iovance Biotherapeutics (IOVA) Competitors $1.75 +0.00 (+0.23%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$1.76 +0.00 (+0.11%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IOVA vs. ARWR, TWST, APLS, VCEL, RXRX, NAMS, APGE, DNLI, KNSA, and CGONShould you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), Apellis Pharmaceuticals (APLS), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), NewAmsterdam Pharma (NAMS), Apogee Therapeutics (APGE), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Iovance Biotherapeutics vs. Its Competitors Arrowhead Pharmaceuticals Twist Bioscience Apellis Pharmaceuticals Vericel Recursion Pharmaceuticals NewAmsterdam Pharma Apogee Therapeutics Denali Therapeutics Kiniksa Pharmaceuticals International CG Oncology Iovance Biotherapeutics (NASDAQ:IOVA) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Does the media prefer IOVA or ARWR? In the previous week, Iovance Biotherapeutics had 27 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 28 mentions for Iovance Biotherapeutics and 1 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.59 beat Iovance Biotherapeutics' score of 0.07 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 24 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is IOVA or ARWR more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -176.49%. Arrowhead Pharmaceuticals' return on equity of -45.33% beat Iovance Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Iovance Biotherapeutics-176.49% -49.71% -39.18% Arrowhead Pharmaceuticals N/A -45.33%-12.49% Do analysts rate IOVA or ARWR? Iovance Biotherapeutics currently has a consensus price target of $12.22, suggesting a potential upside of 596.82%. Arrowhead Pharmaceuticals has a consensus price target of $43.71, suggesting a potential upside of 160.51%. Given Iovance Biotherapeutics' higher possible upside, equities analysts clearly believe Iovance Biotherapeutics is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iovance Biotherapeutics 0 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has preferable valuation and earnings, IOVA or ARWR? Iovance Biotherapeutics has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIovance Biotherapeutics$212.68M2.75-$372.18M-$1.24-1.41Arrowhead Pharmaceuticals$3.55M652.77-$599.49M-$1.40-11.99 Which has more risk and volatility, IOVA or ARWR? Iovance Biotherapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Do institutionals and insiders have more ownership in IOVA or ARWR? 77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 10.3% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryIovance Biotherapeutics beats Arrowhead Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOVA vs. The Competition Export to ExcelMetricIovance BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$584.39M$2.91B$5.56B$9.03BDividend YieldN/A2.44%5.22%3.99%P/E Ratio-1.4121.5627.6920.25Price / Sales2.75241.84389.53161.89Price / CashN/A42.7336.8958.10Price / Book0.757.518.035.67Net Income-$372.18M-$55.14M$3.18B$249.21M7 Day Performance3.79%4.61%2.93%3.28%1 Month Performance-14.44%0.90%1.72%3.95%1 Year Performance-75.91%5.40%34.39%20.98% Iovance Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOVAIovance Biotherapeutics4.7 of 5 stars$1.75+0.2%$12.22+596.8%-75.9%$584.39M$212.68M-1.41500ARWRArrowhead Pharmaceuticals3.9445 of 5 stars$15.99-0.6%$43.71+173.4%-34.4%$2.21B$3.55M-11.42400TWSTTwist Bioscience4.4645 of 5 stars$36.69+2.1%$50.40+37.4%-21.4%$2.20B$312.97M-11.29990Positive NewsAPLSApellis Pharmaceuticals4.4269 of 5 stars$17.45+0.1%$40.05+129.5%-50.4%$2.19B$781.37M-9.75770Trending NewsAnalyst ForecastAnalyst RevisionVCELVericel2.845 of 5 stars$43.37+3.9%$61.14+41.0%-10.5%$2.18B$237.22M1,446.15300News CoveragePositive NewsRXRXRecursion Pharmaceuticals1.9226 of 5 stars$5.07+0.8%$7.00+38.1%-28.1%$2.06B$58.84M-2.86400Analyst ForecastNAMSNewAmsterdam Pharma2.2741 of 5 stars$18.24-1.8%$42.89+135.1%-0.8%$2.05B$45.56M-9.704Positive NewsAnalyst UpgradeAPGEApogee Therapeutics2.8931 of 5 stars$44.12+1.7%$94.60+114.4%+25.1%$2.03BN/A-12.2691News CoverageAnalyst ForecastInsider TradeDNLIDenali Therapeutics4.6319 of 5 stars$13.98-0.9%$33.71+141.2%-30.5%$2.03BN/A-5.24430Positive NewsKNSAKiniksa Pharmaceuticals International3.275 of 5 stars$27.56-1.7%$38.80+40.8%+43.9%$2.01B$423.24M-110.24220Analyst UpgradeCGONCG Oncology2.3557 of 5 stars$26.11+0.6%$58.67+124.7%-15.6%$1.99B$1.14M-17.2961 Related Companies and Tools Related Companies Arrowhead Pharmaceuticals Competitors Twist Bioscience Competitors Apellis Pharmaceuticals Competitors Vericel Competitors Recursion Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Apogee Therapeutics Competitors Denali Therapeutics Competitors Kiniksa Pharmaceuticals International Competitors CG Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOVA) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
